WallStreetZenWallStreetZen

NASDAQ: PVLA
Palvella Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PVLA

Based on 5 analysts offering 12 month price targets for Palvella Therapeutics Inc

Min Forecast
$215.00+73.18%
Avg Forecast
$239.00+92.51%
Max Forecast
$270.00+117.48%

Should I buy or sell PVLA stock?

Based on 5 analysts offering ratings for Palvella Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PVLA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PVLA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their PVLA stock forecasts and price targets.

PVLA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-21
lockedlocked$00.00+00.00%2026-05-21
lockedlocked$00.00+00.00%2026-03-24
lockedlocked$00.00+00.00%2026-02-25
lockedlocked$00.00+00.00%2026-02-25Find Out Why

1 of 1

Forecast return on equity

Is PVLA forecast to generate an efficient return?

Company
36.94%
Industry
90.27%
Market
172.07%
PVLA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PVLA forecast to generate an efficient return on assets?

Company
32.53%
Industry
27.3%
PVLA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PVLA earnings per share forecast

What is PVLA's earnings per share in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
-$5.75
Avg 2 year Forecast
-$6.65
Avg 3 year Forecast
-$4.07

PVLA revenue forecast

What is PVLA's revenue in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$32.1M
Avg 3 year Forecast
$111.2M

PVLA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PVLA$124.15$239.00+92.51%Strong Buy
BCAX$27.15$31.38+15.56%Buy
SRPT$16.83$25.63+52.26%Hold
ABCL$5.80$9.67+66.67%Strong Buy
MRVI$6.99$5.50-21.32%Strong Buy
View Top Biotech Stocks

Palvella Therapeutics Stock Forecast FAQ

Is Palvella Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: PVLA) stock is to Strong Buy PVLA stock.

Out of 5 analysts, 3 (60%) are recommending PVLA as a Strong Buy, 2 (40%) are recommending PVLA as a Buy, 0 (0%) are recommending PVLA as a Hold, 0 (0%) are recommending PVLA as a Sell, and 0 (0%) are recommending PVLA as a Strong Sell.

If you're new to stock investing, here's how to buy Palvella Therapeutics stock.

What is PVLA's earnings growth forecast for 2026-2028?

(NASDAQ: PVLA) Palvella Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.43%.

Palvella Therapeutics's earnings in 2026 is -$49,297,000.On average, 18 Wall Street analysts forecast PVLA's earnings for 2026 to be -$82,521,553, with the lowest PVLA earnings forecast at -$97,126,871, and the highest PVLA earnings forecast at -$65,360,340. On average, 17 Wall Street analysts forecast PVLA's earnings for 2027 to be -$95,395,690, with the lowest PVLA earnings forecast at -$156,864,816, and the highest PVLA earnings forecast at -$23,192,379.

In 2028, PVLA is forecast to generate -$58,416,969 in earnings, with the lowest earnings forecast at -$158,270,415 and the highest earnings forecast at $45,782,358.

What is PVLA's revenue growth forecast for 2026-2028?

(NASDAQ: PVLA) Palvella Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.

Palvella Therapeutics's revenue in 2026 is $0.On average, 17 Wall Street analysts forecast PVLA's revenue for 2026 to be $0, with the lowest PVLA revenue forecast at $0, and the highest PVLA revenue forecast at $0. On average, 17 Wall Street analysts forecast PVLA's revenue for 2027 to be $460,792,549, with the lowest PVLA revenue forecast at $154,615,858, and the highest PVLA revenue forecast at $1,109,920,983.

In 2028, PVLA is forecast to generate $1,595,354,538 in revenue, with the lowest revenue forecast at $1,068,255,021 and the highest revenue forecast at $3,689,840,047.

What is PVLA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PVLA) forecast ROA is 32.53%, which is higher than the forecast US Biotechnology industry average of 27.3%.

What is PVLA's Price Target?

According to 5 Wall Street analysts that have issued a 1 year PVLA price target, the average PVLA price target is $239.00, with the highest PVLA stock price forecast at $270.00 and the lowest PVLA stock price forecast at $215.00.

On average, Wall Street analysts predict that Palvella Therapeutics's share price could reach $239.00 by May 21, 2027. The average Palvella Therapeutics stock price prediction forecasts a potential upside of 92.51% from the current PVLA share price of $124.15.

What is PVLA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PVLA) Palvella Therapeutics's current Earnings Per Share (EPS) is -$4.17. On average, analysts forecast that PVLA's EPS will be -$5.75 for 2026, with the lowest EPS forecast at -$6.77, and the highest EPS forecast at -$4.56. On average, analysts forecast that PVLA's EPS will be -$6.65 for 2027, with the lowest EPS forecast at -$10.94, and the highest EPS forecast at -$1.62. In 2028, PVLA's EPS is forecast to hit -$4.07 (min: -$11.03, max: $3.19).

What is PVLA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PVLA) forecast ROE is 36.94%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.